Pharmamar | Sustainability Performance
A Spanish biopharmaceutical company specializing in marine-derived oncology treatments.
1986
Spain
501 - 1,000 employees
Biotechnology
$100M - 500M in revenue
$1M - 10M in profitability
Sustainability Ranking & Industry Benchmark
#5749
Overall#145
in Spain#110
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
- PharmaMar's pipeline depended on marine compound commercialization.
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$249.4MFY2025 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
43.0%FY2025
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
25.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.2
▼ 16.2%
0.2
▲ 3.8%
0.2
▲ 1.6%
0.6
2030Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Available
Human rights policy
Available
Recycling policy
Available
Workplace health & safety policy
Available
25%
Independent Directors
5 out of 20 incl. management
Overall score
75
Environment
99
Social
99
Governance
28
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
